This is a Validated Antibody Database (VAD) review about human progesterone receptor, based on 162 published articles (read how Labome selects the articles), using progesterone receptor antibody in all methods. It is aimed to help Labome visitors find the most suited progesterone receptor antibody. Please note the number of articles fluctuates since newly identified citations are added and citations for discontinued catalog numbers are removed regularly.
progesterone receptor synonym: NR3C3; PR

Knockout validation
Dako
domestic rabbit polyclonal
  • immunohistochemistry knockout validation; mouse; loading ...; fig 3c
Dako progesterone receptor antibody (Dako, A0098) was used in immunohistochemistry knockout validation on mouse samples (fig 3c). Cell Rep (2020) ncbi
Invitrogen
domestic rabbit monoclonal (SP2)
  • immunohistochemistry; rat; fig 4b
Invitrogen progesterone receptor antibody (Thermo Fisher Scientific, MA5-14505) was used in immunohistochemistry on rat samples (fig 4b). Int J Mol Sci (2021) ncbi
domestic rabbit monoclonal (SP2)
  • immunohistochemistry - frozen section; mouse; 1:200; loading ...; fig 5c
Invitrogen progesterone receptor antibody (Invitrogen, MA5-14505) was used in immunohistochemistry - frozen section on mouse samples at 1:200 (fig 5c). Front Neurosci (2020) ncbi
mouse monoclonal (hPRa 2)
  • immunohistochemistry - paraffin section; cat; loading ...; fig 1b
Invitrogen progesterone receptor antibody (Invitrogen, hPRa 2) was used in immunohistochemistry - paraffin section on cat samples (fig 1b). Sci Rep (2020) ncbi
mouse monoclonal (PgR636)
  • immunohistochemistry - paraffin section; human; 1:50; loading ...
In order to elucidate the clinical importance of IDO1 protein in hormone receptor-positive breast cancer, Invitrogen progesterone receptor antibody (Thermo-Scientific, PGR636) was used in immunohistochemistry - paraffin section on human samples at 1:50. J Immunother Cancer (2017) ncbi
domestic rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; mouse; loading ...; fig 1b
In order to determine if PIK3CA mutations contribute to tumor initiation, Invitrogen progesterone receptor antibody (Thermo Scientific, RM-9102) was used in immunohistochemistry - paraffin section on mouse samples (fig 1b). Oncogenesis (2016) ncbi
domestic rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; human; 1:250; tbl 1
In order to classify triple-negative breast cancer into subtypes, Invitrogen progesterone receptor antibody (Neomarkers, SP2) was used in immunohistochemistry - paraffin section on human samples at 1:250 (tbl 1). Oncol Lett (2016) ncbi
domestic rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; human; 1:200; fig 4a
In order to describe the uterine transcriptome of patients with recurrent/repeated implantation failure, Invitrogen progesterone receptor antibody (Thermo Fisher, PM-9102-S) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 4a). PLoS ONE (2016) ncbi
mouse monoclonal (hPRa2, hPRa3)
  • immunocytochemistry; domestic goat; 1:70; fig 6
In order to analyze progesterone receptor and estrogen receptor 1 in primary goat mammary epithelial cells, Invitrogen progesterone receptor antibody (ThermoFisher Scientific, MA1-12626) was used in immunocytochemistry on domestic goat samples at 1:70 (fig 6). Anim Sci J (2016) ncbi
domestic rabbit monoclonal (SP2)
  • immunohistochemistry; human; 1:300; loading ...
In order to explore the relationship between tumor-infiltrating lymphocytes and the clinical outcomes of triple-negative breast cancers, Invitrogen progesterone receptor antibody (Thermoscientific, SP2) was used in immunohistochemistry on human samples at 1:300. Breast Cancer Res Treat (2016) ncbi
mouse monoclonal (Alpha PR6)
  • immunohistochemistry - paraffin section; mouse; tbl 2
In order to discuss the roles of somatostatin and cortistatin in mammary gland tumorigenesis and metabolic disorders, Invitrogen progesterone receptor antibody (Thermo Scientific, MA1-411) was used in immunohistochemistry - paraffin section on mouse samples (tbl 2). Breast Cancer Res (2016) ncbi
domestic rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; human; 1:200; tbl 1
In order to elucidate the role of Runx2 during the early stages of breast cancer and metastasis, Invitrogen progesterone receptor antibody (Thermo Scientific, SP2) was used in immunohistochemistry - paraffin section on human samples at 1:200 (tbl 1). Pathol Oncol Res (2016) ncbi
domestic rabbit monoclonal (SP2)
  • immunocytochemistry; human; 1:10; fig 1b
In order to analyze propagation of oestrogen-responsive and oestrogen receptor-positive normal human breast cells in culture, Invitrogen progesterone receptor antibody (Labvision, RM-9102-S) was used in immunocytochemistry on human samples at 1:10 (fig 1b). Nat Commun (2015) ncbi
mouse monoclonal (hPRa 6)
  • immunohistochemistry - paraffin section; chicken; 4 ug/ml; fig 2
In order to examine the expression of progesterone receptor isoforms and estrogen receptor alpha in chickens, Invitrogen progesterone receptor antibody (NeoMarkers, hPRa6) was used in immunohistochemistry - paraffin section on chicken samples at 4 ug/ml (fig 2). Acta Histochem (2015) ncbi
mouse monoclonal (hPRa2, hPRa3)
  • immunohistochemistry - paraffin section; chicken; 4 ug/ml; fig 2
In order to examine the expression of progesterone receptor isoforms and estrogen receptor alpha in chickens, Invitrogen progesterone receptor antibody (NeoMarkers, hPRa2+hPRa3) was used in immunohistochemistry - paraffin section on chicken samples at 4 ug/ml (fig 2). Acta Histochem (2015) ncbi
domestic rabbit monoclonal (SP2)
  • immunohistochemistry; human; 1:1000; fig 6
In order to present two cases of primary sclerosing epithelioid fibrosarcoma of the kidney, Invitrogen progesterone receptor antibody (Thermo, SP2) was used in immunohistochemistry on human samples at 1:1000 (fig 6). Diagn Pathol (2015) ncbi
mouse monoclonal (PgR636)
  • immunohistochemistry - paraffin section; human
In order to analyze how aggressiveness and invasiveness of human breast carcinoma is correlated with hexokinase and phosphofructokinase kinase and intracellular distribution, Invitrogen progesterone receptor antibody (Thermo Scientific, PgR636) was used in immunohistochemistry - paraffin section on human samples . Oncotarget (2015) ncbi
domestic rabbit monoclonal (SP2)
  • immunohistochemistry; human; 1:100
In order to evaluate the expression of CD24, CD44, CD133 and ALDH1 in invasive ductal carcinoma of the breast, Invitrogen progesterone receptor antibody (Thermo Scientific, RM-9102-S1) was used in immunohistochemistry on human samples at 1:100. Pathol Res Pract (2015) ncbi
domestic rabbit monoclonal (SP2)
  • western blot; mouse; 1:200
In order to elucidate the potential of PIK3CA to induce multipotency during tumorigenesis in the mammary gland, Invitrogen progesterone receptor antibody (Thermo Scientific, Rm9102) was used in western blot on mouse samples at 1:200. Nature (2015) ncbi
domestic rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; human; 1:200; tbl 2
In order to characterize triple-negative breast cancer and the role of epithelial-mesenchymal transition markers, Invitrogen progesterone receptor antibody (Thermo Lab Vision, RM-9102-S) was used in immunohistochemistry - paraffin section on human samples at 1:200 (tbl 2). Breast Cancer Res Treat (2015) ncbi
mouse monoclonal (hPRa 7)
  • immunohistochemistry - paraffin section; mouse; fig 4
In order to propose that RANK dictates WNT responsiveness to hormone-induced changes in adult mammary cells, Invitrogen progesterone receptor antibody (Thermo Scientific, MA5-12658) was used in immunohistochemistry - paraffin section on mouse samples (fig 4). Stem Cell Reports (2015) ncbi
domestic rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; human; 1:200
In order to assess the clinicopathological and immunohistochemical characteristics, and the clinical outcomes, between screen-detected and symptomatic DCIS, Invitrogen progesterone receptor antibody (Thermo Scientific Lab Vision, RM-9102-S) was used in immunohistochemistry - paraffin section on human samples at 1:200. Breast Cancer Res Treat (2015) ncbi
mouse monoclonal (PgR636)
  • immunohistochemistry; human; 1:1000
Invitrogen progesterone receptor antibody (Thermo Scientific, PgR636) was used in immunohistochemistry on human samples at 1:1000. Breast (2015) ncbi
domestic rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; human
In order to discuss how to treat the four types of breast cancer, Invitrogen progesterone receptor antibody (Thermo Scientific Lab Vision, SP2) was used in immunohistochemistry - paraffin section on human samples . Niger J Clin Pract (2015) ncbi
domestic rabbit monoclonal (SP2)
  • immunohistochemistry; human; 1:200
In order to evaluate the presence of cancer stem cells and EMT markers as prognostic markers for breast metaplastic carcinoma, Invitrogen progesterone receptor antibody (Neomarker, RM-9102-S) was used in immunohistochemistry on human samples at 1:200. Breast Cancer Res Treat (2015) ncbi
domestic rabbit monoclonal (SP2)
  • western blot; human; fig 3
In order to use a cell culture model for aromatase inhibitor-resistant breast cancer to show how fulvestrant treatment and cross-resistance between exemestane and letrozole shows sensitivity, Invitrogen progesterone receptor antibody (Neomarkers, RM-9102) was used in western blot on human samples (fig 3). Int J Oncol (2015) ncbi
mouse monoclonal (Alpha PR6)
  • immunohistochemistry - paraffin section; mouse; 1:500
In order to study the role of progesterone on global stem cell function by serially transplanting mouse mammary epithelia, Invitrogen progesterone receptor antibody (Thermo Fisher Scientific, MA1-411) was used in immunohistochemistry - paraffin section on mouse samples at 1:500. EMBO J (2015) ncbi
domestic rabbit monoclonal (SP2)
  • immunohistochemistry; human; 1:200
In order to evaluate the prevalence, characteristics, prognosis, and effective treatment modalities in patients with primary squamous cell carcinoma of the breast, Invitrogen progesterone receptor antibody (Zymed, SP2) was used in immunohistochemistry on human samples at 1:200. Breast Cancer Res Treat (2015) ncbi
mouse monoclonal (PgR636)
  • immunohistochemistry - paraffin section; human; 1:300
Invitrogen progesterone receptor antibody (Lab Vision, PGR636) was used in immunohistochemistry - paraffin section on human samples at 1:300. Int J Cosmet Sci (2015) ncbi
domestic rabbit monoclonal (SP2)
In order to examine possible factors that affect the type of breast cancer tumors in mice, Invitrogen progesterone receptor antibody (Fisher Scientific, RM-9102-S0) was used . Cancer Res (2014) ncbi
mouse monoclonal (hPRa 7)
  • immunohistochemistry - paraffin section; mouse; 1:50
In order to study how Tip30 regulates FoxA1 expression and the differentiation of murine mammary luminal progenitor to estrogen receptor-positive luminal cell, Invitrogen progesterone receptor antibody (Labvision, hPRa7) was used in immunohistochemistry - paraffin section on mouse samples at 1:50. Cell Death Dis (2014) ncbi
domestic rabbit monoclonal (SP2)
  • immunocytochemistry; human; 1:25
  • immunohistochemistry; human; 1:25
In order to investigate the role of CEACAM6 in luminal, HER2-enriched, and basal-like breast cancers, Invitrogen progesterone receptor antibody (Thermo Scientific, Sp2) was used in immunocytochemistry on human samples at 1:25 and in immunohistochemistry on human samples at 1:25. Am J Pathol (2014) ncbi
mouse monoclonal (hPRa 7)
  • immunocytochemistry; mouse
In order to enhance our understanding of Brca2, Pten and p53 in breast cancer development, Invitrogen progesterone receptor antibody (ThermoScientific, hPRa7) was used in immunocytochemistry on mouse samples . J Pathol (2014) ncbi
domestic rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; human; 1:2000
In order to determine breast cancr stem cells and the lack of correlation of stem cell markers, Invitrogen progesterone receptor antibody (LabVision, SP2) was used in immunohistochemistry - paraffin section on human samples at 1:2000. Br J Cancer (2014) ncbi
domestic rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; human
  • immunocytochemistry; human
In order to study the role of TWIST1 in the mechanism by which KLF17 induces epithelial-to-mesenchymal transition in endometrioid endometrial cancer, Invitrogen progesterone receptor antibody (Lab Vision, SP2) was used in immunohistochemistry - paraffin section on human samples and in immunocytochemistry on human samples . Carcinogenesis (2014) ncbi
mouse monoclonal (608)
  • western blot; human; fig 3
In order to characterize the N-terminal common docking domain of the progesterone receptor, Invitrogen progesterone receptor antibody (Lab Vision, MS-1332) was used in western blot on human samples (fig 3). Nucleic Acids Res (2013) ncbi
mouse monoclonal (hPRa2, hPRa3)
  • chromatin immunoprecipitation; human; fig 7
  • western blot; human; fig 3
In order to characterize the N-terminal common docking domain of the progesterone receptor, Invitrogen progesterone receptor antibody (ThermoScientific, MS-298-P) was used in chromatin immunoprecipitation on human samples (fig 7) and in western blot on human samples (fig 3). Nucleic Acids Res (2013) ncbi
domestic rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; human; 1:200; fig 2
In order to study triple negative breast cancer in Chinese women, Invitrogen progesterone receptor antibody (Zymed, clone SP2) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 2). Int J Clin Exp Pathol (2013) ncbi
domestic rabbit monoclonal (SP2)
  • immunohistochemistry; human
In order to report and characterize two cases of accessory breast cancer occurring concurrently with primary invasive breast cancer, Invitrogen progesterone receptor antibody (Zymed, SP2) was used in immunohistochemistry on human samples . Cancer Biol Med (2012) ncbi
domestic rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; human; 1:100; tbl 2
In order to correlate expression of HER2, ER, PR, Ki-67, and CK5 with breast cancer reoccurrence, Invitrogen progesterone receptor antibody (Neomarkers, SP2) was used in immunohistochemistry - paraffin section on human samples at 1:100 (tbl 2). Breast Cancer (Auckl) (2013) ncbi
domestic rabbit monoclonal (SP2)
  • immunohistochemistry; human; 1:500; tbl 1
In order to study the expression of estrogen and progesterone receptors in low-grade ovarian serous carcinomas and the significance for hormone therapy, Invitrogen progesterone receptor antibody (Thermo Scientific, SP2) was used in immunohistochemistry on human samples at 1:500 (tbl 1). Gynecol Oncol (2013) ncbi
domestic rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; dogs; 1:200
In order to measure the expression of ENO1 and assess its significance in canine mammary carcinoma, Invitrogen progesterone receptor antibody (Thermo Scientific, SP2) was used in immunohistochemistry - paraffin section on dogs samples at 1:200. BMC Vet Res (2011) ncbi
mouse monoclonal (hPRa 7)
  • western blot; human; 4 ug/ml; fig 5
In order to test the efficacy of mifepristone treatment on various cancers, Invitrogen progesterone receptor antibody (Thermo Fisher, hPRa7) was used in western blot on human samples at 4 ug/ml (fig 5). BMC Cancer (2011) ncbi
domestic rabbit monoclonal (SP2)
  • immunohistochemistry; mouse; 1:200; fig 1
In order to elucidate the contribution of PIK3CA H1047R to breast cancer pathogenesis, Invitrogen progesterone receptor antibody (Thermo, RM-9102) was used in immunohistochemistry on mouse samples at 1:200 (fig 1). Cancer Res (2011) ncbi
domestic rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; human; 1:200
In order to study EGFR gene in triple negative breast cancer and its therapeutic application, Invitrogen progesterone receptor antibody (Neomarker, RM9102-S) was used in immunohistochemistry - paraffin section on human samples at 1:200. Breast Cancer Res (2011) ncbi
domestic rabbit monoclonal (SP2)
  • immunohistochemistry - paraffin section; human; 1:250; fig 2, 3, 4
  • immunohistochemistry; human; 1:250
In order to report a new clinical case of prostatic adenomas with abnormal p63 expression, Invitrogen progesterone receptor antibody (NeoMarkers, SP2) was used in immunohistochemistry - paraffin section on human samples at 1:250 (fig 2, 3, 4) and in immunohistochemistry on human samples at 1:250. Int J Surg Pathol (2011) ncbi
Santa Cruz Biotechnology
mouse monoclonal (AB-52)
  • immunohistochemistry - paraffin section; mouse; 1:300; loading ...; fig 9a
Santa Cruz Biotechnology progesterone receptor antibody (Santa Cruz, sc-810) was used in immunohistochemistry - paraffin section on mouse samples at 1:300 (fig 9a). Am J Transl Res (2021) ncbi
mouse monoclonal (AB-52)
  • western blot; human; loading ...; fig 8d
Santa Cruz Biotechnology progesterone receptor antibody (Santa Cruz, sc-810) was used in western blot on human samples (fig 8d). Stem Cell Res Ther (2019) ncbi
mouse monoclonal (B-30)
  • western blot; human; 1:2000; loading ...; fig 1b
Santa Cruz Biotechnology progesterone receptor antibody (Santa, sc-811) was used in western blot on human samples at 1:2000 (fig 1b). Biosci Rep (2019) ncbi
mouse monoclonal
  • western blot; human; 1:5000; loading ...; fig 1b
Santa Cruz Biotechnology progesterone receptor antibody (Santa, sc-398898) was used in western blot on human samples at 1:5000 (fig 1b). Biosci Rep (2019) ncbi
mouse monoclonal (C262)
  • western blot; human; 1:1000; loading ...; fig 1b
Santa Cruz Biotechnology progesterone receptor antibody (Santa, sc-53943) was used in western blot on human samples at 1:1000 (fig 1b). Biosci Rep (2019) ncbi
mouse monoclonal (AB-52)
  • immunohistochemistry - paraffin section; human; 1:100; fig 1
Santa Cruz Biotechnology progesterone receptor antibody (Santa Cruz, sc-810) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 1). Arch Med Sci (2017) ncbi
Abcam
domestic rabbit monoclonal (YR85)
  • immunohistochemistry - paraffin section; human; 1:50; loading ...; fig 1d
Abcam progesterone receptor antibody (Abcam, ab32085) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig 1d). Cell Death Dis (2021) ncbi
domestic rabbit monoclonal (YR85)
  • mass cytometry; human; loading ...; fig 3a
Abcam progesterone receptor antibody (Abcam, ab32085) was used in mass cytometry on human samples (fig 3a). Cell (2019) ncbi
domestic rabbit monoclonal (SP2)
  • immunohistochemistry; rat; 1:100; loading ...; fig 3d
Abcam progesterone receptor antibody (Abcam, ab16661) was used in immunohistochemistry on rat samples at 1:100 (fig 3d). PLoS Genet (2019) ncbi
domestic rabbit monoclonal (YR85)
  • other; human; loading ...; fig 4c
Abcam progesterone receptor antibody (Abcam, ab32085) was used in other on human samples (fig 4c). Cancer Cell (2018) ncbi
domestic rabbit monoclonal (YR85)
  • immunohistochemistry - paraffin section; rat; 1:100; loading ...; fig st13
In order to outline the protocols for antibodies used for immunohistochemical studies, Abcam progesterone receptor antibody (Abcam, ab32085) was used in immunohistochemistry - paraffin section on rat samples at 1:100 (fig st13). J Toxicol Pathol (2017) ncbi
Abnova
domestic rabbit monoclonal (A21-W)
  • immunohistochemistry - paraffin section; mouse; 1:400
In order to determine the role of Tbx3 in different cell types present in the adult mammary gland, Abnova progesterone receptor antibody (Abnova, MAB9785) was used in immunohistochemistry - paraffin section on mouse samples at 1:400. PLoS ONE (2014) ncbi
domestic rabbit monoclonal (A21-W)
  • immunohistochemistry - paraffin section; mouse; 1:400
Abnova progesterone receptor antibody (Abnova, MAB9785) was used in immunohistochemistry - paraffin section on mouse samples at 1:400. Breast Cancer Res (2014) ncbi
Dako
mouse monoclonal (PgR 636)
  • immunohistochemistry; human; 1:100; fig 7b
Dako progesterone receptor antibody (Dako, PgR636) was used in immunohistochemistry on human samples at 1:100 (fig 7b). Biomedicines (2021) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; mouse; 1:2000; loading ...; fig s2a
Dako progesterone receptor antibody (Dako, A0098) was used in immunohistochemistry - paraffin section on mouse samples at 1:2000 (fig s2a). Cancer Res (2021) ncbi
mouse monoclonal (PgR 1294)
  • immunohistochemistry; human; 1:100; loading ...; fig 1d
Dako progesterone receptor antibody (Dako, M3568) was used in immunohistochemistry on human samples at 1:100 (fig 1d). Proc Natl Acad Sci U S A (2021) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry; human; 1:200; loading ...
Dako progesterone receptor antibody (DAKO, pgR636) was used in immunohistochemistry on human samples at 1:200. Cancers (Basel) (2020) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry; human; 1:100; loading ...; tbl 1
Dako progesterone receptor antibody (Dako, PgR636) was used in immunohistochemistry on human samples at 1:100 (tbl 1). Mod Pathol (2020) ncbi
domestic rabbit polyclonal
  • immunohistochemistry knockout validation; mouse; loading ...; fig 3c
Dako progesterone receptor antibody (Dako, A0098) was used in immunohistochemistry knockout validation on mouse samples (fig 3c). Cell Rep (2020) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry - paraffin section; human; 1:70; loading ...; tbl 1
Dako progesterone receptor antibody (Dako, PgR 636) was used in immunohistochemistry - paraffin section on human samples at 1:70 (tbl 1). Breast Cancer Res (2020) ncbi
mouse monoclonal (PgR 1294)
  • immunohistochemistry; human; 1:200; loading ...; fig 1b
Dako progesterone receptor antibody (DAKO, M3568) was used in immunohistochemistry on human samples at 1:200 (fig 1b). Breast Cancer Res (2019) ncbi
mouse monoclonal (PgR 1294)
  • immunohistochemistry - paraffin section; human; loading ...; fig 1a
Dako progesterone receptor antibody (DAKO, 1294) was used in immunohistochemistry - paraffin section on human samples (fig 1a). J Histochem Cytochem (2019) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry - paraffin section; human; 1:150; fig 2a
Dako progesterone receptor antibody (Dako, M3569) was used in immunohistochemistry - paraffin section on human samples at 1:150 (fig 2a). Cell (2018) ncbi
mouse monoclonal (1294)
  • immunocytochemistry; human; 1:500; loading ...; fig 2e
  • western blot; human; loading ...; fig 2c
Dako progesterone receptor antibody (Dako, 1294) was used in immunocytochemistry on human samples at 1:500 (fig 2e) and in western blot on human samples (fig 2c). Oncogene (2017) ncbi
domestic rabbit polyclonal
  • immunohistochemistry; mouse; loading ...; fig 4d
Dako progesterone receptor antibody (DAKO, A0098) was used in immunohistochemistry on mouse samples (fig 4d). Proc Natl Acad Sci U S A (2017) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; mouse; 1:500; loading ...; fig af4b
In order to investigate estrogen receptor alpha positive breast cancer, Dako progesterone receptor antibody (Dako, A0098) was used in immunohistochemistry - paraffin section on mouse samples at 1:500 (fig af4b). Breast Cancer Res (2017) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry; human; 1:10; tbl 1
Dako progesterone receptor antibody (Dako, PgR 636) was used in immunohistochemistry on human samples at 1:10 (tbl 1). Cancer (2017) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; mouse; 1:50; loading ...; fig 1d
In order to examine the differentiation potential of adult mammary stem cells, Dako progesterone receptor antibody (DAKO, A0098) was used in immunohistochemistry - paraffin section on mouse samples at 1:50 (fig 1d). Nat Commun (2016) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; mouse; fig s11
Dako progesterone receptor antibody (Dako, A0098) was used in immunohistochemistry - paraffin section on mouse samples (fig s11). Cell Res (2016) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry - paraffin section; human; 1:200; loading ...; tbl 1
In order to examine the association between pretreatment molecular and clinical factors and axillary lymph node metastases in early breast cancer, Dako progesterone receptor antibody (Dako, PgR 636) was used in immunohistochemistry - paraffin section on human samples at 1:200 (tbl 1). Medicine (Baltimore) (2016) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry - paraffin section; human; 1:800; loading ...; tbl 1
In order to study the role of cell polarity determinant human Discs-large in endometrial cancer, Dako progesterone receptor antibody (DAKO, M3569) was used in immunohistochemistry - paraffin section on human samples at 1:800 (tbl 1). Br J Cancer (2016) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry - paraffin section; human; 1:150
In order to identify prognostic indicators of resected early stage 'pure' and 'mixed' lobular breast cancer by using subpopulation treatment effect pattern plot (STEPP) analysis of Ki67 histology assay, Dako progesterone receptor antibody (Dako, PgR 636) was used in immunohistochemistry - paraffin section on human samples at 1:150. J Exp Clin Cancer Res (2016) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry - paraffin section; human; 1:50; tbl 1
In order to research the association of breast cancer susceptibility and polymorphisms of glutathione S-transferase pi and toll-like receptors 2 and 9, Dako progesterone receptor antibody (Dako, M3569) was used in immunohistochemistry - paraffin section on human samples at 1:50 (tbl 1). Oncol Lett (2016) ncbi
mouse monoclonal (PgR 1294)
  • immunohistochemistry; human; 1:200; tbl 2
In order to characterize eleven cases of primary glial and neuronal tumors of the ovary or peritoneum, Dako progesterone receptor antibody (Dako, PgR1294) was used in immunohistochemistry on human samples at 1:200 (tbl 2). Am J Surg Pathol (2016) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry - paraffin section; human; 1:50; fig s1
In order to utilize ovarian cancer xenograft models to study dynamic modulation of phosphoprotein expression, Dako progesterone receptor antibody (Dako, 3569) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig s1). BMC Cancer (2016) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry; human; tbl 1
In order to compare and correlate AIB1 expression before and after the development of tamoxifen resistance, Dako progesterone receptor antibody (Dako, M3569) was used in immunohistochemistry on human samples (tbl 1). PLoS ONE (2016) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry - paraffin section; human; 1:50; loading ...; tbl s5
In order to explore the relationship between hnRNP A1 and RON tumoral expression, Dako progesterone receptor antibody (Dako, PgR636) was used in immunohistochemistry - paraffin section on human samples at 1:50 (tbl s5). Oncotarget (2016) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; mouse; fig 3
Dako progesterone receptor antibody (Dako, A0098) was used in immunohistochemistry - paraffin section on mouse samples (fig 3). Proc Natl Acad Sci U S A (2016) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry - paraffin section; human; 1:150
In order to characterize aggressive tumors in African breast cancer and the strong expression of hypoxia-inducible factor-1 alpha (HIF-1alpha) and its association with Axl expression, Dako progesterone receptor antibody (Dako, M3569) was used in immunohistochemistry - paraffin section on human samples at 1:150. PLoS ONE (2016) ncbi
mouse monoclonal (PgR 636)
  • immunocytochemistry; human; 1:10; fig s13b
In order to analyze propagation of oestrogen-responsive and oestrogen receptor-positive normal human breast cells in culture, Dako progesterone receptor antibody (Dako, M356901-2) was used in immunocytochemistry on human samples at 1:10 (fig s13b). Nat Commun (2015) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - free floating section; rat; 1:400; fig 3
In order to study prolactin secretion in female rats and oestrogen regulation of luteinising hormone by the hypothalamic effects of tamoxifen, Dako progesterone receptor antibody (Dako, A0098) was used in immunohistochemistry - free floating section on rat samples at 1:400 (fig 3). J Neuroendocrinol (2016) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry - paraffin section; human; 1:50; fig 2
In order to analyze metastatic breast cancer and the expression of lipid metabolism-related proteins, Dako progesterone receptor antibody (DAKO, M3569) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig 2). PLoS ONE (2015) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry; human; 1:200; fig 1
Dako progesterone receptor antibody (DAKO, PgR636) was used in immunohistochemistry on human samples at 1:200 (fig 1). Virchows Arch (2015) ncbi
mouse monoclonal (PgR 1294)
  • immunohistochemistry - paraffin section; human; loading ...
In order to develop a non-cross-reactive multiplex to measure 8 common breast cancer biomarkers, Dako progesterone receptor antibody (Dako, PgR 1294) was used in immunohistochemistry - paraffin section on human samples . Appl Immunohistochem Mol Morphol (2016) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry; human; 1:400
In order to investigate markers expressed by stromal cells in breast cancer patients, Dako progesterone receptor antibody (DakoCytomation, M3569) was used in immunohistochemistry on human samples at 1:400. Mol Clin Oncol (2015) ncbi
mouse monoclonal (PgR 1294)
  • immunohistochemistry - paraffin section; human; 1:1000; tbl 1
In order to characterize a quantitative method of metastasis assessment called Menacalc that is a prognostic marker for axillary node-negative breast cancer, Dako progesterone receptor antibody (DAKO, PgR1294) was used in immunohistochemistry - paraffin section on human samples at 1:1000 (tbl 1). BMC Cancer (2015) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry; human
Dako progesterone receptor antibody (Dako, M3569) was used in immunohistochemistry on human samples . BMC Clin Pathol (2015) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry; human
Dako progesterone receptor antibody (Dako, PgR636) was used in immunohistochemistry on human samples . Breast Cancer Res Treat (2015) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry; human
Dako progesterone receptor antibody (Dako, clone PgR636) was used in immunohistochemistry on human samples . Brain Tumor Pathol (2015) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry; human; 1:250
In order to compare the immunohistochemical and genetic profiles found in the three types of endometrial carcinomas, Dako progesterone receptor antibody (Dako, PgR 636) was used in immunohistochemistry on human samples at 1:250. Gynecol Oncol (2015) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry - paraffin section; human; 1:70
In order to identify clinicopathologic factors associated with sentinel lymph node metastasis, Dako progesterone receptor antibody (Dako, PgR 636) was used in immunohistochemistry - paraffin section on human samples at 1:70. Cancer Res Treat (2016) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry - paraffin section; human
In order to determine of the effects of 1-year endocrine therapy in patients with breast cancer, Dako progesterone receptor antibody (Dako, PgR636) was used in immunohistochemistry - paraffin section on human samples . Pathol Oncol Res (2015) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry - paraffin section; human; 1:50; tbl 4
In order to characterize different breast cancer subtypes and differential expression of lipid metabolism-related proteins, Dako progesterone receptor antibody (DAKO, M3569) was used in immunohistochemistry - paraffin section on human samples at 1:50 (tbl 4). PLoS ONE (2015) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry - paraffin section; human; 1:250
In order to describe a patient diagnosed with a noninvasive intestinal-type mucinous ovarian borderline tumor presenting with pleural metastases, Dako progesterone receptor antibody (DAKO, PgR636) was used in immunohistochemistry - paraffin section on human samples at 1:250. Int J Gynecol Pathol (2015) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry; human; 1:150
In order to discuss the use of an intraoperative frozen section procedure during treatment for breast cancer, Dako progesterone receptor antibody (Dako, PgR636) was used in immunohistochemistry on human samples at 1:150. Balkan Med J (2014) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry; human; 1:100; loading ...
In order to identify the cancer-associated fibroblast phenotype in different subtypes of breast cancer., Dako progesterone receptor antibody (DAKO, M3569) was used in immunohistochemistry on human samples at 1:100. Breast Cancer Res Treat (2015) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry; human; 1:50
Dako progesterone receptor antibody (DakoCytomation, PgR 636) was used in immunohistochemistry on human samples at 1:50. BMC Cancer (2014) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry - paraffin section; human; 1:500
Dako progesterone receptor antibody (Dako, PGR 636) was used in immunohistochemistry - paraffin section on human samples at 1:500. Cancer Lett (2015) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry - paraffin section; human; 53.8 mg/l
Dako progesterone receptor antibody (DAKO, PgR 636) was used in immunohistochemistry - paraffin section on human samples at 53.8 mg/l. Oncotarget (2014) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry - paraffin section; human; ready-to-use
Dako progesterone receptor antibody (DAKO, PgR636) was used in immunohistochemistry - paraffin section on human samples at ready-to-use. Malays J Pathol (2014) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry; human; 1:1000
Dako progesterone receptor antibody (Dako, PgR636) was used in immunohistochemistry on human samples at 1:1000. BMC Womens Health (2014) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry; human; 1:100
Dako progesterone receptor antibody (Dako, 636) was used in immunohistochemistry on human samples at 1:100. Anticancer Res (2014) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry - paraffin section; human; 1:500
Dako progesterone receptor antibody (DAKO, PgR636) was used in immunohistochemistry - paraffin section on human samples at 1:500. Am J Clin Pathol (2014) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry - paraffin section; human; 1:800; tbl 2
Dako progesterone receptor antibody (Dako, PgR636) was used in immunohistochemistry - paraffin section on human samples at 1:800 (tbl 2). Oncotarget (2014) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry - paraffin section; human; 1:200; fig 2
In order to study triple negative primary breast cancer biological characteristics and clinical outcome in older women in comparison to their younger counterparts, Dako progesterone receptor antibody (Dako, PgR 636) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 2). PLoS ONE (2014) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry; human; 1:250
Dako progesterone receptor antibody (Dako, PgR636) was used in immunohistochemistry on human samples at 1:250. Virchows Arch (2014) ncbi
mouse monoclonal (PgR 636)
  • immunocytochemistry; human; 1:100
  • immunohistochemistry; human; 1:100
In order to investigate the role of CEACAM6 in luminal, HER2-enriched, and basal-like breast cancers, Dako progesterone receptor antibody (Dako, Pgr636) was used in immunocytochemistry on human samples at 1:100 and in immunohistochemistry on human samples at 1:100. Am J Pathol (2014) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry - paraffin section; human; 1:70
Dako progesterone receptor antibody (Dako, PgR 636) was used in immunohistochemistry - paraffin section on human samples at 1:70. Mod Pathol (2014) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry; human; 1:50
In order to study treatment resistance mechanisms in triple-negative breast cancers, Dako progesterone receptor antibody (DAKO, PgR636) was used in immunohistochemistry on human samples at 1:50. Cancer Discov (2014) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry; human; 1:1000
Dako progesterone receptor antibody (Dako, PgR636) was used in immunohistochemistry on human samples at 1:1000. Horm Cancer (2014) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry - paraffin section; human; 1:200
In order to determine the expression of LHRH receptor, progesterone receptor, and Ki67 labeling index in patients with meningioma, Dako progesterone receptor antibody (Dako, M3569) was used in immunohistochemistry - paraffin section on human samples at 1:200. Prostate Cancer Prostatic Dis (2013) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry - paraffin section; human; 1:2000
Dako progesterone receptor antibody (DAKO, PGR636) was used in immunohistochemistry - paraffin section on human samples at 1:2000. Int J Cancer (2014) ncbi
mouse monoclonal (PgR 1294)
  • immunocytochemistry; human
Dako progesterone receptor antibody (Dako, M3568) was used in immunocytochemistry on human samples . Endocrinology (2013) ncbi
mouse monoclonal (PgR 1294)
  • immunohistochemistry; human; tbl 1
In order to study the expression of estrogen and progesterone receptors in low-grade ovarian serous carcinomas and the significance for hormone therapy, Dako progesterone receptor antibody (DAKO, PGR1294) was used in immunohistochemistry on human samples (tbl 1). Gynecol Oncol (2013) ncbi
mouse monoclonal (PgR 636)
  • immunohistochemistry; human; 1:6
Dako progesterone receptor antibody (Dako Cytomation, PgR 636) was used in immunohistochemistry on human samples at 1:6. Pathol Int (2011) ncbi
Cell Signaling Technology
domestic rabbit monoclonal (D8Q2J)
  • other; human; 1:100; loading ...; fig 2a
Cell Signaling Technology progesterone receptor antibody (Cell Signaling, 8757) was used in other on human samples at 1:100 (fig 2a). Proc Natl Acad Sci U S A (2021) ncbi
domestic rabbit monoclonal (D8Q2J)
  • western blot; human; 1:1000; loading ...; fig 3c
Cell Signaling Technology progesterone receptor antibody (Cell Signaling, 8757S) was used in western blot on human samples at 1:1000 (fig 3c). Toxicol Sci (2021) ncbi
domestic rabbit monoclonal (D8Q2J)
  • immunohistochemistry; human; loading ...
Cell Signaling Technology progesterone receptor antibody (Cell Signaling, D8Q2J) was used in immunohistochemistry on human samples . Oncogene (2020) ncbi
domestic rabbit monoclonal (D8Q2J)
  • western blot; human; loading ...; fig 1a
Cell Signaling Technology progesterone receptor antibody (CST, 8757) was used in western blot on human samples (fig 1a). Cell Commun Signal (2019) ncbi
domestic rabbit monoclonal (D8Q2J)
  • immunohistochemistry; human; 1:200; loading ...; fig 4c
  • western blot; human; 1:1000; loading ...; fig 4b
Cell Signaling Technology progesterone receptor antibody (Cell Signaling, 8757S) was used in immunohistochemistry on human samples at 1:200 (fig 4c) and in western blot on human samples at 1:1000 (fig 4b). Endocrinology (2019) ncbi
domestic rabbit monoclonal (C1A2)
  • immunohistochemistry - paraffin section; human; 1:200; fig 4g
Cell Signaling Technology progesterone receptor antibody (Cell signaling, 3157S) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 4g). Reprod Biol Endocrinol (2017) ncbi
domestic rabbit polyclonal
  • western blot; human; loading ...; fig 2a
Cell Signaling Technology progesterone receptor antibody (Cell Signaling, 3171) was used in western blot on human samples (fig 2a). Oncotarget (2016) ncbi
domestic rabbit polyclonal
  • immunohistochemistry - paraffin section; human; 1:25; fig s1
In order to utilize ovarian cancer xenograft models to study dynamic modulation of phosphoprotein expression, Cell Signaling Technology progesterone receptor antibody (Cell Signaling, 3176) was used in immunohistochemistry - paraffin section on human samples at 1:25 (fig s1). BMC Cancer (2016) ncbi
domestic rabbit monoclonal (C89F7)
  • western blot; human; fig 1
Cell Signaling Technology progesterone receptor antibody (Cell Signaling, 3153) was used in western blot on human samples (fig 1). PLoS ONE (2016) ncbi
domestic rabbit monoclonal (C1A2)
  • western blot; human; fig 1
Cell Signaling Technology progesterone receptor antibody (Cell Signaling, 3157) was used in western blot on human samples (fig 1). PLoS ONE (2016) ncbi
domestic rabbit monoclonal (C1A2)
  • immunocytochemistry; human; fig 3b
In order to explore the link between HDAC1 and progesterone receptor A in myometrium samples, Cell Signaling Technology progesterone receptor antibody (Cell Signaling, 3157) was used in immunocytochemistry on human samples (fig 3b). Reprod Sci (2016) ncbi
domestic rabbit polyclonal
  • western blot; human; 1:1000; loading ...; fig 5c
Cell Signaling Technology progesterone receptor antibody (Cell Signaling, 3176) was used in western blot on human samples at 1:1000 (fig 5c). Mol Med Rep (2016) ncbi
domestic rabbit monoclonal (C89F7)
  • immunohistochemistry - paraffin section; human; 1:100; fig 2
In order to test if osteoblasts regulate the intratumoral steroidogenesis of castration-resistant prostate cancer, Cell Signaling Technology progesterone receptor antibody (Cell signaling, C89F7) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 2). Mol Cell Endocrinol (2016) ncbi
domestic rabbit monoclonal (D8Q2J)
  • western blot; mouse; 1:500; fig s6
In order to analyze the regulation of gestational length in caspase-3 and -7 dependent involving uterine endoplasmic reticulum stress-unfolded protein response, Cell Signaling Technology progesterone receptor antibody (Cell Signaling Technology, 8757) was used in western blot on mouse samples at 1:500 (fig s6). Proc Natl Acad Sci U S A (2015) ncbi
domestic rabbit monoclonal (C1A2)
  • immunocytochemistry; human; fig 3
In order to use of estrogen receptor-positive breast cancer lines to study steroid induction of therapy-resistant cytokeratin-5-positive cells through a BCL6-dependent mechanism, Cell Signaling Technology progesterone receptor antibody (Cell signaling, 3157S) was used in immunocytochemistry on human samples (fig 3). Oncogene (2016) ncbi
domestic rabbit monoclonal (C1A2)
  • western blot; human; loading ...; fig 1a
Cell Signaling Technology progesterone receptor antibody (Cell Signaling, 3157) was used in western blot on human samples (fig 1a). Oncotarget (2015) ncbi
Ventana
domestic rabbit monoclonal (1E2)
  • immunohistochemistry; human; 1:250; loading ...
Ventana progesterone receptor antibody (Ventana, 1E2) was used in immunohistochemistry on human samples at 1:250. Mod Pathol (2020) ncbi
domestic rabbit monoclonal (1E2)
  • immunohistochemistry; human; 1:50; loading ...; fig 3b
Ventana progesterone receptor antibody (Ventana, 790-2223) was used in immunohistochemistry on human samples at 1:50 (fig 3b). Oncogene (2018) ncbi
domestic rabbit monoclonal (1E2)
  • immunohistochemistry - paraffin section; human; loading ...; fig 2b
In order to investigate the interaction between breast cancer subtype and treatment using data from a breast cancer trial randomizing women to adjuvant chemotherapy, Ventana progesterone receptor antibody (Ventana, 1E2) was used in immunohistochemistry - paraffin section on human samples (fig 2b). Clin Cancer Res (2017) ncbi
domestic rabbit monoclonal (1E2)
  • immunohistochemistry; human; fig 1a
Ventana progesterone receptor antibody (Ventana, 790-2223) was used in immunohistochemistry on human samples (fig 1a). Oncotarget (2016) ncbi
domestic rabbit monoclonal (1E2)
  • immunohistochemistry - paraffin section; human; 1:1; tbl 3
In order to characterize the spindle cell type of metaplastic breast carcinoma with myoepithelial features and report that this subtype exhibits a higher frequency of PIK3CA mutation than other types of metaplastic breast carcinoma, Ventana progesterone receptor antibody (Ventana, 1E2) was used in immunohistochemistry - paraffin section on human samples at 1:1 (tbl 3). Virchows Arch (2016) ncbi
domestic rabbit monoclonal (1E2)
  • immunohistochemistry - paraffin section; cat; loading ...; tbl 4
In order to develop an assay to measure serum HER2 in order to diagnose cats with mammary carcinomas, Ventana progesterone receptor antibody (Ventana, 1E2) was used in immunohistochemistry - paraffin section on cat samples (tbl 4). Oncotarget (2016) ncbi
domestic rabbit monoclonal (1E2)
  • immunohistochemistry; cat; loading ...; fig 1b
In order to describe the clinical, pathological, and immunophenotypic features collected from 61 queens with feline mammary carcinoma, Ventana progesterone receptor antibody (Ventana, 1E2) was used in immunohistochemistry on cat samples (fig 1b). Tumour Biol (2016) ncbi
Vector Laboratories
  • immunocytochemistry; human; 1:25; fig s13a
In order to analyze propagation of oestrogen-responsive and oestrogen receptor-positive normal human breast cells in culture, Vector Laboratories progesterone receptor antibody (Vector Laboratories, VP-P987) was used in immunocytochemistry on human samples at 1:25 (fig s13a). Nat Commun (2015) ncbi
Leica Biosystems
mouse monoclonal (6F11)
  • immunohistochemistry; mouse; 1:50; loading ...; fig 2d
Leica Biosystems progesterone receptor antibody (Novocastra, NCL-ER-6F11) was used in immunohistochemistry on mouse samples at 1:50 (fig 2d). Oncol Lett (2021) ncbi
mouse monoclonal (6F11)
  • western blot; human; loading ...; fig 3e
Leica Biosystems progesterone receptor antibody (Novocastra Leica Biosystems, NCL-ER-6F11) was used in western blot on human samples (fig 3e). Oncogene (2019) ncbi
mouse monoclonal (16)
  • immunohistochemistry - paraffin section; human; 1:400; loading ...; fig st13
  • immunohistochemistry - paraffin section; mouse; 1:400; loading ...; fig st13
In order to outline the protocols for antibodies used for immunohistochemical studies, Leica Biosystems progesterone receptor antibody (Leica, NCL-PGR-312) was used in immunohistochemistry - paraffin section on human samples at 1:400 (fig st13) and in immunohistochemistry - paraffin section on mouse samples at 1:400 (fig st13). J Toxicol Pathol (2017) ncbi
mouse monoclonal (1A6)
  • immunohistochemistry - paraffin section; human; 1:40; loading ...; fig 6e
Leica Biosystems progesterone receptor antibody (Novocastra, 1A6) was used in immunohistochemistry - paraffin section on human samples at 1:40 (fig 6e). J Pathol (2017) ncbi
mouse monoclonal (1A6)
  • immunohistochemistry - paraffin section; human; 1:40; loading ...; fig 4
Leica Biosystems progesterone receptor antibody (Novocastra, 1A6) was used in immunohistochemistry - paraffin section on human samples at 1:40 (fig 4). Taiwan J Obstet Gynecol (2016) ncbi
mouse monoclonal (6F11)
  • immunoprecipitation; human; loading ...; fig 5a
  • western blot; human; 1:1000; loading ...; fig 4e
Leica Biosystems progesterone receptor antibody (Novacastra, NCL-ER-6F11) was used in immunoprecipitation on human samples (fig 5a) and in western blot on human samples at 1:1000 (fig 4e). Oncogene (2017) ncbi
mouse monoclonal (6F11)
  • immunohistochemistry - paraffin section; rat; loading ...; fig 1
In order to investigate the contribution of PI3K/AKT pathway to the development of radiation carcinogenesis, Leica Biosystems progesterone receptor antibody (Leica Microsystems, 6F11) was used in immunohistochemistry - paraffin section on rat samples (fig 1). J Radiat Res (2017) ncbi
mouse monoclonal (6F11)
  • immunohistochemistry - paraffin section; human; loading ...; tbl 1
  • immunocytochemistry; human; loading ...; fig S2G
Leica Biosystems progesterone receptor antibody (Leica, 6F11) was used in immunohistochemistry - paraffin section on human samples (tbl 1) and in immunocytochemistry on human samples (fig S2G). Oncotarget (2016) ncbi
mouse monoclonal
  • immunohistochemistry; human; 1:150; fig 2c
In order to characterize and present the features observed in sixteen cases of solid pseudopapillary neoplasm of the pancreas, Leica Biosystems progesterone receptor antibody (Novocastra, NCL-L-PGR-312) was used in immunohistochemistry on human samples at 1:150 (fig 2c). Kaohsiung J Med Sci (2016) ncbi
monoclonal (16)
  • immunohistochemistry; human; loading ...
In order to report the clinicopathological features and prognostic factors of pregnancy-associated gastric cancer, Leica Biosystems progesterone receptor antibody (Novocastra, 16) was used in immunohistochemistry on human samples . Gut Liver (2016) ncbi
mouse monoclonal (6F11)
  • immunohistochemistry; human; loading ...
In order to report the clinicopathological features and prognostic factors of pregnancy-associated gastric cancer, Leica Biosystems progesterone receptor antibody (Novocastra, 6F11) was used in immunohistochemistry on human samples . Gut Liver (2016) ncbi
mouse monoclonal (6F11)
  • immunohistochemistry - paraffin section; human; 1:35; loading ...; tbl 2
In order to present the clinicopathological features of nine cases of renal cell carcinoma metastatic to the ovary or the fallopian tube, Leica Biosystems progesterone receptor antibody (Leica Biosystems, 6F11) was used in immunohistochemistry - paraffin section on human samples at 1:35 (tbl 2). Hum Pathol (2016) ncbi
mouse monoclonal (6F11)
  • immunohistochemistry; human; 1:35; tbl 2
In order to characterize eleven cases of primary glial and neuronal tumors of the ovary or peritoneum, Leica Biosystems progesterone receptor antibody (Leica Microsystems, 6F11) was used in immunohistochemistry on human samples at 1:35 (tbl 2). Am J Surg Pathol (2016) ncbi
mouse monoclonal (6F11)
  • immunohistochemistry - paraffin section; human; 1:70; fig 1b
In order to study markers of the epithelial to mesenchymal transition using invasive lobular carcinoma samples, Leica Biosystems progesterone receptor antibody (Novocastra, 6F11) was used in immunohistochemistry - paraffin section on human samples at 1:70 (fig 1b). J Pathol (2016) ncbi
mouse monoclonal (1A6)
  • immunohistochemistry - paraffin section; human; 1:50; fig 1b
In order to study markers of the epithelial to mesenchymal transition using invasive lobular carcinoma samples, Leica Biosystems progesterone receptor antibody (Novocastra, 1A6) was used in immunohistochemistry - paraffin section on human samples at 1:50 (fig 1b). J Pathol (2016) ncbi
  • western blot; human; 1:10,000; fig 1b
Leica Biosystems progesterone receptor antibody (Novocastra, NCL-L-PGR-312/2) was used in western blot on human samples at 1:10,000 (fig 1b). PLoS ONE (2015) ncbi
mouse monoclonal (6F11)
  • western blot; human; fig 3
Leica Biosystems progesterone receptor antibody (Novocastra, 6F11) was used in western blot on human samples (fig 3). Oncotarget (2015) ncbi
monoclonal (16)
  • western blot; human; fig 3
Leica Biosystems progesterone receptor antibody (Novocastra, 16) was used in western blot on human samples (fig 3). Oncotarget (2015) ncbi
monoclonal (16)
  • immunohistochemistry; human; loading ...
In order to report the demographic characteristics, recurrence pattern, and survival rate in Colombian females with breast cancer, Leica Biosystems progesterone receptor antibody (Leica Biosystems, 16) was used in immunohistochemistry on human samples . Ecancermedicalscience (2015) ncbi
mouse monoclonal (6F11)
  • immunohistochemistry - paraffin section; human; loading ...
In order to develop a non-cross-reactive multiplex to measure 8 common breast cancer biomarkers, Leica Biosystems progesterone receptor antibody (Leica, 6F11) was used in immunohistochemistry - paraffin section on human samples . Appl Immunohistochem Mol Morphol (2016) ncbi
mouse monoclonal (6F11)
  • immunohistochemistry - paraffin section; human; tbl 2
Leica Biosystems progesterone receptor antibody (Novocastra, 6F11) was used in immunohistochemistry - paraffin section on human samples (tbl 2). Int J Clin Exp Pathol (2015) ncbi
mouse monoclonal (16)
  • immunohistochemistry; human; 1:1000; fig s7
Leica Biosystems progesterone receptor antibody (Leica, NCL-PgR-AB) was used in immunohistochemistry on human samples at 1:1000 (fig s7). Nature (2015) ncbi
mouse monoclonal
  • immunohistochemistry; human; 1:400
In order to evaluate the potential protein markers of bone metastases in breast cancer patients, Leica Biosystems progesterone receptor antibody (Novocastra, NCL-L-PGR-312) was used in immunohistochemistry on human samples at 1:400. Pathol Oncol Res (2015) ncbi
mouse monoclonal (SAN27)
  • immunohistochemistry - paraffin section; human
Leica Biosystems progesterone receptor antibody (Novocastra, NCL-PGR-B) was used in immunohistochemistry - paraffin section on human samples . Breast Cancer Res Treat (2015) ncbi
mouse monoclonal (16)
  • immunohistochemistry - paraffin section; human
Leica Biosystems progesterone receptor antibody (Novocastra, NCL-PGR-312) was used in immunohistochemistry - paraffin section on human samples . Breast Cancer Res Treat (2015) ncbi
monoclonal (16)
  • immunohistochemistry - paraffin section; human; 1:100
In order to describe an unusual case of a recurrent dural neoplasm, Leica Biosystems progesterone receptor antibody (Novocastra, 16) was used in immunohistochemistry - paraffin section on human samples at 1:100. Hum Pathol (2015) ncbi
mouse monoclonal (6F11)
  • immunohistochemistry - paraffin section; human; 1:50
Leica Biosystems progesterone receptor antibody (Novocastra Lab, 6F11) was used in immunohistochemistry - paraffin section on human samples at 1:50. Hum Pathol (2015) ncbi
mouse monoclonal (6F11)
  • immunohistochemistry - paraffin section; cat; 1:40
Leica Biosystems progesterone receptor antibody (Novocastra, 6F11) was used in immunohistochemistry - paraffin section on cat samples at 1:40. J Comp Pathol (2015) ncbi
mouse monoclonal (6F11)
  • immunohistochemistry - paraffin section; human
Leica Biosystems progesterone receptor antibody (Novocastra, NCL-ER-6F11) was used in immunohistochemistry - paraffin section on human samples . J Clin Pathol (2015) ncbi
mouse monoclonal (16)
  • immunohistochemistry - paraffin section; human
Leica Biosystems progesterone receptor antibody (Novocastra, NCL-PGR-312) was used in immunohistochemistry - paraffin section on human samples . J Clin Pathol (2015) ncbi
mouse monoclonal (6F11)
  • immunohistochemistry - paraffin section; human; 1:100
Leica Biosystems progesterone receptor antibody (Leica Biosystems, NCL-ER-6F11) was used in immunohistochemistry - paraffin section on human samples at 1:100. Int J Gynecol Pathol (2015) ncbi
mouse monoclonal (6F11)
  • immunohistochemistry - paraffin section; mouse; 1:100
In order to determine the role of Tbx3 in different cell types present in the adult mammary gland, Leica Biosystems progesterone receptor antibody (Novocastra, NCL-ER-6F11) was used in immunohistochemistry - paraffin section on mouse samples at 1:100. PLoS ONE (2014) ncbi
mouse monoclonal (6F11)
  • immunohistochemistry - paraffin section; human; 1:100; loading ...; fig 1b
Leica Biosystems progesterone receptor antibody (Novocastra, NCL-ER-6F11) was used in immunohistochemistry - paraffin section on human samples at 1:100 (fig 1b). Asian J Androl (2015) ncbi
mouse monoclonal (6F11)
  • immunohistochemistry - frozen section; human; 1:100
Leica Biosystems progesterone receptor antibody (Leica Microsystems, 6F11) was used in immunohistochemistry - frozen section on human samples at 1:100. Hum Reprod (2014) ncbi
mouse monoclonal (1A6)
  • immunohistochemistry; human
In order to measure protein expression of insulin-like growth factor receptor pathway members and evaluate their prognostic significance across the different early breast cancer subtypes, Leica Biosystems progesterone receptor antibody (Novocastra, 1A6) was used in immunohistochemistry on human samples . PLoS ONE (2014) ncbi
mouse monoclonal (6F11)
  • immunohistochemistry; human
In order to measure protein expression of insulin-like growth factor receptor pathway members and evaluate their prognostic significance across the different early breast cancer subtypes, Leica Biosystems progesterone receptor antibody (Novocastra, 6F11) was used in immunohistochemistry on human samples . PLoS ONE (2014) ncbi
mouse monoclonal (6F11)
  • immunohistochemistry - paraffin section; mouse; 1:100
Leica Biosystems progesterone receptor antibody (Novocastra, NCL-ER-6 F11) was used in immunohistochemistry - paraffin section on mouse samples at 1:100. Breast Cancer Res (2014) ncbi
mouse monoclonal (1A6)
  • immunohistochemistry; human
In order to study salivary duct carcinoma with rhabdoid features, Leica Biosystems progesterone receptor antibody (Novocastra Laboratories, 1A6) was used in immunohistochemistry on human samples . Head Neck (2014) ncbi
monoclonal
  • immunohistochemistry - paraffin section; human
In order to identify the origin of ovarian Brenner tumour, Leica Biosystems progesterone receptor antibody (Leica Microsystems, RTU-PGR-312) was used in immunohistochemistry - paraffin section on human samples . Eur J Cancer (2013) ncbi
mouse monoclonal (6F11)
  • immunohistochemistry - paraffin section; human; 1:40; fig 1
In order to investigate the contribution of the PI3K/Akt pathway to trastuzumab resistance, Leica Biosystems progesterone receptor antibody (Novocastra, 6F11) was used in immunohistochemistry - paraffin section on human samples at 1:40 (fig 1). Br J Cancer (2012) ncbi
monoclonal (16)
  • immunohistochemistry - paraffin section; human; 1:200; fig 1
In order to investigate the contribution of the PI3K/Akt pathway to trastuzumab resistance, Leica Biosystems progesterone receptor antibody (Novocastra, 16) was used in immunohistochemistry - paraffin section on human samples at 1:200 (fig 1). Br J Cancer (2012) ncbi
mouse monoclonal (1A6)
  • immunohistochemistry; human; 1:200; fig 4
In order to explore the molecular basis of the different ultrasonic patterns of the human endometrium and the molecular marker basis of local injury, Leica Biosystems progesterone receptor antibody (Leica, 1A6) was used in immunohistochemistry on human samples at 1:200 (fig 4). PLoS ONE (2012) ncbi
Articles Reviewed
  1. Hsu C, Hsu L, Hsueh Y, Lin C, Chang H, Hsu C. Ovarian Folliculogenesis and Uterine Endometrial Receptivity after Intermittent Vaginal Injection of Recombinant Human Follicle-Stimulating Hormone in Infertile Women Receiving In Vitro Fertilization and in Immature Female Rats. Int J Mol Sci. 2021;22: pubmed publisher
  2. Machida Y, Imai T. Different properties of mammary carcinogenesis induced by two chemical carcinogens, DMBA and PhIP, in heterozygous BALB/c Trp53 knockout mice. Oncol Lett. 2021;22:738 pubmed publisher
  3. Aleksandrovych V, Wrona A, Bereza T, Pitynski K, Gil K. Oviductal Telocytes in Patients with Uterine Myoma. Biomedicines. 2021;9: pubmed publisher
  4. Noreldin A, Gewaily M, Saadeldin I, Abomughaid M, Khafaga A, Elewa Y. Osteoblast-activating peptide exhibits a specific distribution pattern in mouse ovary and may regulate ovarian steroids and local calcium levels. Am J Transl Res. 2021;13:5796-5814 pubmed
  5. Laine A, Nagelli S, Farrington C, Butt U, Cvrljevic A, Vainonen J, et al. CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis. Cancer Res. 2021;81:4319-4331 pubmed publisher
  6. Ma X, Zhao T, Yan H, Guo K, Liu Z, Wei L, et al. Fatostatin reverses progesterone resistance by inhibiting the SREBP1-NF-κB pathway in endometrial carcinoma. Cell Death Dis. 2021;12:544 pubmed publisher
  7. Guzeloglu Kayisli O, Semerci N, Guo X, Larsen K, Ozmen A, Arlier S, et al. Decidual cell FKBP51-progesterone receptor binding mediates maternal stress-induced preterm birth. Proc Natl Acad Sci U S A. 2021;118: pubmed publisher
  8. Duijndam B, Goudriaan A, van den Hoorn T, van der Stel W, Le Dévédec S, Bouwman P, et al. Physiologically Relevant Estrogen Receptor Alpha Pathway Reporters for Single-Cell Imaging-Based Carcinogenic Hazard Assessment of Estrogenic Compounds. Toxicol Sci. 2021;181:187-198 pubmed publisher
  9. Erber R, Meyer J, Taubert H, Fasching P, Wach S, Haberle L, et al. PIWI-Like 1 and PIWI-Like 2 Expression in Breast Cancer. Cancers (Basel). 2020;12: pubmed publisher
  10. Christgen M, Bartels S, van Luttikhuizen J, Bublitz J, Rieger L, Christgen H, et al. E-cadherin to P-cadherin switching in lobular breast cancer with tubular elements. Mod Pathol. 2020;33:2483-2498 pubmed publisher
  11. Park C, Lin P, Zhou S, Barakat R, Bashir S, Choi J, et al. Progesterone Receptor Serves the Ovary as a Trigger of Ovulation and a Terminator of Inflammation. Cell Rep. 2020;31:107496 pubmed publisher
  12. Kim M, Chung Y, Kim H, Woo J, Ahn S, Park S. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast. Breast Cancer Res. 2020;22:32 pubmed publisher
  13. Lozzi B, Huang T, Sardar D, Huang A, Deneen B. Regionally Distinct Astrocytes Display Unique Transcription Factor Profiles in the Adult Brain. Front Neurosci. 2020;14:61 pubmed publisher
  14. Kluz P, Kolb R, Xie Q, Borcherding N, Liu Q, Luo Y, et al. Cancer cell-intrinsic function of CD177 in attenuating β-catenin signaling. Oncogene. 2020;39:2877-2889 pubmed publisher
  15. Granados Soler J, Bornemann Kolatzki K, Beck J, Brenig B, Schütz E, Betz D, et al. Analysis of Copy-Number Variations and Feline Mammary Carcinoma Survival. Sci Rep. 2020;10:1003 pubmed publisher
  16. Davaadelger B, Choi M, Singhal H, Clare S, Khan S, Kim J. BRCA1 mutation influences progesterone response in human benign mammary organoids. Breast Cancer Res. 2019;21:124 pubmed publisher
  17. Jiang S, Zhang M, Zhang Y, Zhou W, Zhu T, Ruan Q, et al. WNT5B governs the phenotype of basal-like breast cancer by activating WNT signaling. Cell Commun Signal. 2019;17:109 pubmed publisher
  18. Li B, Zhang Q, Sun J, Lai D. Human amniotic epithelial cells improve fertility in an intrauterine adhesion mouse model. Stem Cell Res Ther. 2019;10:257 pubmed publisher
  19. Haider S, Gamperl M, Burkard T, Kunihs V, Kaindl U, Junttila S, et al. Estrogen Signaling Drives Ciliogenesis in Human Endometrial Organoids. Endocrinology. 2019;160:2282-2297 pubmed publisher
  20. Zhang L, Feng Q, Wang Z, Liu P, Cui S. Progesterone receptor antagonist provides palliative effects for uterine leiomyoma through a Bcl-2/Beclin1-dependent mechanism. Biosci Rep. 2019;39: pubmed publisher
  21. Wagner J, Rapsomaniki M, Chevrier S, Anzeneder T, Langwieder C, Dykgers A, et al. A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer. Cell. 2019;177:1330-1345.e18 pubmed publisher
  22. Ding L, Shunkwiler L, Harper N, Zhao Y, Hinohara K, Huh S, et al. Deletion of Cdkn1b in ACI rats leads to increased proliferation and pregnancy-associated changes in the mammary gland due to perturbed systemic endocrine environment. PLoS Genet. 2019;15:e1008002 pubmed publisher
  23. Sompuram S, Vani K, Schaedle A, Balasubramanian A, Bogen S. Selecting an Optimal Positive IHC Control for Verifying Antigen Retrieval. J Histochem Cytochem. 2019;67:275-289 pubmed publisher
  24. Domenici G, Aurrekoetxea Rodríguez I, Simões B, Rábano M, Lee S, Millán J, et al. A Sox2-Sox9 signalling axis maintains human breast luminal progenitor and breast cancer stem cells. Oncogene. 2019;38:3151-3169 pubmed publisher
  25. Ng P, Li J, Jeong K, Shao S, Chen H, Tsang Y, et al. Systematic Functional Annotation of Somatic Mutations in Cancer. Cancer Cell. 2018;33:450-462.e10 pubmed publisher
  26. Browne A, Charmsaz S, Varešlija D, Fagan A, Cosgrove N, Cocchiglia S, et al. Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer. Oncogene. 2018;37:2008-2021 pubmed publisher
  27. Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F, et al. A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. Cell. 2018;172:373-386.e10 pubmed publisher
  28. Carvajal Hausdorf D, Mani N, Velcheti V, Schalper K, Rimm D. Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer. J Immunother Cancer. 2017;5:81 pubmed publisher
  29. Fettig L, McGinn O, Finlay Schultz J, LaBarbera D, Nordeen S, Sartorius C. Cross talk between progesterone receptors and retinoic acid receptors in regulation of cytokeratin 5-positive breast cancer cells. Oncogene. 2017;36:6074-6084 pubmed publisher
  30. Ran H, Kong S, Zhang S, Cheng J, Zhou C, He B, et al. Nuclear Shp2 directs normal embryo implantation via facilitating the ERα tyrosine phosphorylation by the Src kinase. Proc Natl Acad Sci U S A. 2017;114:4816-4821 pubmed publisher
  31. Wu D, Kimura F, Zheng L, Ishida M, Niwa Y, Hirata K, et al. Chronic endometritis modifies decidualization in human endometrial stromal cells. Reprod Biol Endocrinol. 2017;15:16 pubmed publisher
  32. Furukawa S, Nagaike M, Ozaki K. Databases for technical aspects of immunohistochemistry. J Toxicol Pathol. 2017;30:79-107 pubmed publisher
  33. Méndez López L, Zavala Pompa A, Cortés Gutiérrez E, Cerda Flores R, Dávila Rodríguez M. Leptin receptor expression during the progression of endometrial carcinoma is correlated with estrogen and progesterone receptors. Arch Med Sci. 2017;13:228-235 pubmed publisher
  34. Barcus C, O Leary K, Brockman J, Rugowski D, Liu Y, Garcia N, et al. Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells. Breast Cancer Res. 2017;19:9 pubmed publisher
  35. Winder A, Maniar K, Wei J, Liu D, Scholtens D, Lurain J, et al. Synuclein-γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. Cancer. 2017;123:1144-1155 pubmed publisher
  36. Corda G, Sala G, Lattanzio R, Iezzi M, Sallese M, Fragassi G, et al. Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer. J Pathol. 2017;241:350-361 pubmed publisher
  37. Piasecka D, Kitowska K, Czaplinska D, Mieczkowski K, Mieszkowska M, Turczyk L, et al. Fibroblast growth factor signalling induces loss of progesterone receptor in breast cancer cells. Oncotarget. 2016;7:86011-86025 pubmed publisher
  38. Sheen M, Marotti J, Allegrezza M, Rutkowski M, Conejo Garcia J, Fiering S. Constitutively activated PI3K accelerates tumor initiation and modifies histopathology of breast cancer. Oncogenesis. 2016;5:e267 pubmed publisher
  39. Davis F, Lloyd Lewis B, Harris O, Kozar S, Winton D, Muresan L, et al. Single-cell lineage tracing in the mammary gland reveals stochastic clonal dispersion of stem/progenitor cell progeny. Nat Commun. 2016;7:13053 pubmed publisher
  40. Loverro G, Resta L, Dellino M, Edoardo D, Cascarano M, Loverro M, et al. Uterine and ovarian changes during testosterone administration in young female-to-male transsexuals. Taiwan J Obstet Gynecol. 2016;55:686-691 pubmed publisher
  41. Harrod A, Fulton J, Nguyen V, Periyasamy M, Ramos Garcia L, Lai C, et al. Genomic modelling of the ESR1 Y537S mutation for evaluating function and new therapeutic approaches for metastatic breast cancer. Oncogene. 2017;36:2286-2296 pubmed publisher
  42. Showler K, Nishimura M, Daino K, Imaoka T, Nishimura Y, Morioka T, et al. Analysis of genes involved in the PI3K/Akt pathway in radiation- and MNU-induced rat mammary carcinomas. J Radiat Res. 2017;58:183-194 pubmed publisher
  43. Nielsen T, Jensen M, Burugu S, Gao D, Jørgensen C, Balslev E, et al. High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial. Clin Cancer Res. 2017;23:946-953 pubmed publisher
  44. Di Franco S, Turdo A, Benfante A, Colorito M, Gaggianesi M, Apuzzo T, et al. ?Np63 drives metastasis in breast cancer cells via PI3K/CD44v6 axis. Oncotarget. 2016;7:54157-54173 pubmed publisher
  45. Ladd B, Mazzola A, Bihani T, Lai Z, BRADFORD J, Collins M, et al. Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations. Oncotarget. 2016;7:54120-54136 pubmed publisher
  46. Ugras N, Yerci O, Coşkun S, Ocakoglu G, Sarkut P, Dündar H. Retrospective analysis of clinicopathological features of solid pseudopapillary neoplasm of the pancreas. Kaohsiung J Med Sci. 2016;32:356-61 pubmed publisher
  47. Liu Y, Wang K, Xing H, Zhai X, Wang L, Wang W. Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers. Oncol Lett. 2016;12:1240-1256 pubmed
  48. Choi Y, Kim H, Lim E, Park M, Yoon J, Kim Y, et al. Integrative Analyses of Uterine Transcriptome and MicroRNAome Reveal Compromised LIF-STAT3 Signaling and Progesterone Response in the Endometrium of Patients with Recurrent/Repeated Implantation Failure (RIF). PLoS ONE. 2016;11:e0157696 pubmed publisher
  49. Sigl V, Owusu Boaitey K, Joshi P, Kavirayani A, Wirnsberger G, Novatchkova M, et al. RANKL/RANK control Brca1 mutation- . Cell Res. 2016;26:761-74 pubmed publisher
  50. Leo F, Bartels S, Mägel L, Framke T, Büsche G, Jonigk D, et al. Prognostic factors in the myoepithelial-like spindle cell type of metaplastic breast cancer. Virchows Arch. 2016;469:191-201 pubmed publisher
  51. Chung M, Lee J, Kim S, Suh Y, Choi H. Simple Prediction Model of Axillary Lymph Node Positivity After Analyzing Molecular and Clinical Factors in Early Breast Cancer. Medicine (Baltimore). 2016;95:e3689 pubmed publisher
  52. Song M, Park Y, Song H, Park S, Ahn J, Choi K, et al. Prognosis of Pregnancy-Associated Gastric Cancer: An Age-, Sex-, and Stage-Matched Case-Control Study. Gut Liver. 2016;10:731-8 pubmed publisher
  53. Liang L, Huang H, Dadhania V, Zhang J, Zhang M, Liu J. Renal cell carcinoma metastatic to the ovary or fallopian tube: a clinicopathological study of 9 cases. Hum Pathol. 2016;51:96-102 pubmed publisher
  54. Ogorevc J, Dovc P. Expression of estrogen receptor 1 and progesterone receptor in primary goat mammary epithelial cells. Anim Sci J. 2016;87:1464-1471 pubmed publisher
  55. Sugihara T, Nakagawa S, Sasajima Y, Ichinose T, Hiraike H, Kondo F, et al. Loss of the cell polarity determinant human Discs-large is a novel molecular marker of nodal involvement and poor prognosis in endometrial cancer. Br J Cancer. 2016;114:1012-8 pubmed publisher
  56. Carbognin L, Sperduti I, Brunelli M, Marcolini L, Nortilli R, Pilotto S, et al. Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of Ki67 assay according to histology: prognostic relevance for resected early stage 'pure' and 'mixed' lobular breast cancer. J Exp Clin Cancer Res. 2016;35:50 pubmed publisher
  57. Al Harras M, Houssen M, Shaker M, Farag K, Farouk O, Monir R, et al. Polymorphisms of glutathione S-transferase ? 1 and toll-like receptors 2 and 9: Association with breast cancer susceptibility. Oncol Lett. 2016;11:2182-2188 pubmed
  58. Liang L, Olar A, Niu N, Jiang Y, Cheng W, Bian X, et al. Primary Glial and Neuronal Tumors of the Ovary or Peritoneum: A Clinicopathologic Study of 11 Cases. Am J Surg Pathol. 2016;40:847-56 pubmed publisher
  59. Koussounadis A, Langdon S, Um I, Kay C, Francis K, Harrison D, et al. Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models. BMC Cancer. 2016;16:205 pubmed publisher
  60. Matsumoto H, Thike A, Li H, Yeong J, Koo S, Dent R, et al. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer. Breast Cancer Res Treat. 2016;156:237-47 pubmed publisher
  61. Alkner S, Bendahl P, Ehinger A, Lövgren K, Rydén L, Fernö M. Prior Adjuvant Tamoxifen Treatment in Breast Cancer Is Linked to Increased AIB1 and HER2 Expression in Metachronous Contralateral Breast Cancer. PLoS ONE. 2016;11:e0150977 pubmed publisher
  62. Luque R, Villa Osaba A, L López F, Pozo Salas A, Sánchez Sánchez R, Ortega Salas R, et al. Lack of cortistatin or somatostatin differentially influences DMBA-induced mammary gland tumorigenesis in mice in an obesity-dependent mode. Breast Cancer Res. 2016;18:29 pubmed publisher
  63. Cammas A, Lacroix Triki M, Pierredon S, Le Bras M, Iacovoni J, Teulade Fichou M, et al. hnRNP A1-mediated translational regulation of the G quadruplex-containing RON receptor tyrosine kinase mRNA linked to tumor progression. Oncotarget. 2016;7:16793-805 pubmed publisher
  64. Soares M, Ribeiro R, Najmudin S, Gameiro A, Rodrigues R, Cardoso F, et al. Serum HER2 levels are increased in cats with mammary carcinomas and predict tissue HER2 status. Oncotarget. 2016;7:17314-26 pubmed publisher
  65. Kavlashvili T, Jia Y, Dai D, Meng X, Thiel K, Leslie K, et al. Inverse Relationship between Progesterone Receptor and Myc in Endometrial Cancer. PLoS ONE. 2016;11:e0148912 pubmed publisher
  66. Su R, Strug M, Jeong J, Miele L, Fazleabas A. Aberrant activation of canonical Notch1 signaling in the mouse uterus decreases progesterone receptor by hypermethylation and leads to infertility. Proc Natl Acad Sci U S A. 2016;113:2300-5 pubmed publisher
  67. Nalwoga H, Ahmed L, Arnes J, Wabinga H, Akslen L. Strong Expression of Hypoxia-Inducible Factor-1α (HIF-1α) Is Associated with Axl Expression and Features of Aggressive Tumors in African Breast Cancer. PLoS ONE. 2016;11:e0146823 pubmed publisher
  68. Ke W, Chen C, Luo H, Tang J, Zhang Y, Gao W, et al. Histone Deacetylase 1 Regulates the Expression of Progesterone Receptor A During Human Parturition by Occupying the Progesterone Receptor A Promoter. Reprod Sci. 2016;23:955-64 pubmed publisher
  69. Chen X, Dong X, Gao H, Jiang Y, Jin Y, Chang Y, et al. Suppression of HSP27 increases the anti‑tumor effects of quercetin in human leukemia U937 cells. Mol Med Rep. 2016;13:689-96 pubmed publisher
  70. El Gendi S, Mostafa M. Runx2 Expression as a Potential Prognostic Marker in Invasive Ductal Breast Carcinoma. Pathol Oncol Res. 2016;22:461-70 pubmed publisher
  71. Hagberg Thulin M, Nilsson M, Thulin P, Céraline J, Ohlsson C, Damber J, et al. Osteoblasts promote castration-resistant prostate cancer by altering intratumoral steroidogenesis. Mol Cell Endocrinol. 2016;422:182-191 pubmed publisher
  72. Fridriksdottir A, Kim J, Villadsen R, Klitgaard M, Hopkinson B, Petersen O, et al. Propagation of oestrogen receptor-positive and oestrogen-responsive normal human breast cells in culture. Nat Commun. 2015;6:8786 pubmed publisher
  73. Aquino N, Araujo Lopes R, Batista I, Henriques P, Poletini M, Franci C, et al. Hypothalamic Effects of Tamoxifen on Oestrogen Regulation of Luteinising Hormone and Prolactin Secretion in Female Rats. J Neuroendocrinol. 2016;28: pubmed publisher
  74. González Morán M. Immunohistochemical localization of progesterone receptor isoforms and estrogen receptor alpha in the chicken oviduct magnum during development. Acta Histochem. 2015;117:681-7 pubmed publisher
  75. McCart Reed A, Kutasovic J, Vargas A, Jayanthan J, Al Murrani A, Reid L, et al. An epithelial to mesenchymal transition programme does not usually drive the phenotype of invasive lobular carcinomas. J Pathol. 2016;238:489-94 pubmed publisher
  76. Kyathanahalli C, Organ K, Moreci R, Anamthathmakula P, Hassan S, Caritis S, et al. Uterine endoplasmic reticulum stress-unfolded protein response regulation of gestational length is caspase-3 and -7-dependent. Proc Natl Acad Sci U S A. 2015;112:14090-5 pubmed publisher
  77. Soares M, Correia J, Peleteiro M, Ferreira F. St Gallen molecular subtypes in feline mammary carcinoma and paired metastases-disease progression and clinical implications from a 3-year follow-up study. Tumour Biol. 2016;37:4053-64 pubmed publisher
  78. Esber N, Le Billan F, Resche Rigon M, Loosfelt H, Lombès M, Chabbert Buffet N. Ulipristal Acetate Inhibits Progesterone Receptor Isoform A-Mediated Human Breast Cancer Proliferation and BCl2-L1 Expression. PLoS ONE. 2015;10:e0140795 pubmed publisher
  79. Ertoy Baydar D, Kosemehmetoglu K, Aydin O, Bridge J, Buyukeren B, Aki F. Primary sclerosing epithelioid fibrosarcoma of kidney with variant histomorphologic features: report of 2 cases and review of the literature. Diagn Pathol. 2015;10:186 pubmed publisher
  80. Iriondo O, Rábano M, Domenici G, Carlevaris O, López Ruiz J, Zabalza I, et al. Distinct breast cancer stem/progenitor cell populations require either HIF1α or loss of PHD3 to expand under hypoxic conditions. Oncotarget. 2015;6:31721-39 pubmed publisher
  81. Jung Y, Kim H, Koo J. Expression of Lipid Metabolism-Related Proteins in Metastatic Breast Cancer. PLoS ONE. 2015;10:e0137204 pubmed publisher
  82. Coelho R, Calaça I, Celestrini D, Correia Carneiro A, Costa M, Zancan P, et al. Hexokinase and phosphofructokinase activity and intracellular distribution correlate with aggressiveness and invasiveness of human breast carcinoma. Oncotarget. 2015;6:29375-87 pubmed publisher
  83. Gómez R, Ossa C, Montoya M, Echeverri C, Ángel G, Ascuntar J, et al. Impact of immunohistochemistry-based molecular subtype on chemosensitivity and survival in Hispanic breast cancer patients following neoadjuvant chemotherapy. Ecancermedicalscience. 2015;9:562 pubmed publisher
  84. KapucuoÄŸlu N, Bozkurt K, BaÅŸpınar Å, Koçer M, EroÄŸlu H, Akdeniz R, et al. The clinicopathological and prognostic significance of CD24, CD44, CD133, ALDH1 expressions in invasive ductal carcinoma of the breast: CD44/CD24 expression in breast cancer. Pathol Res Pract. 2015;211:740-7 pubmed publisher
  85. Kim H, Lee K, Park I, Chung Y, Im S, Noh D, et al. Expression of SIRT1 and apoptosis-related proteins is predictive for lymph node metastasis and disease-free survival in luminal A breast cancer. Virchows Arch. 2015;467:563-70 pubmed publisher
  86. Koren S, Reavie L, Couto J, De Silva D, Stadler M, Roloff T, et al. PIK3CA(H1047R) induces multipotency and multi-lineage mammary tumours. Nature. 2015;525:114-8 pubmed publisher
  87. Wang D, Pang Z, Clarke G, Nofech Mozes S, Liu K, Cheung A, et al. Ki-67 Membranous Staining: Biologically Relevant or an Artifact of Multiplexed Immunofluorescent Staining. Appl Immunohistochem Mol Morphol. 2016;24:447-52 pubmed publisher
  88. Liew P, Hsu C, Liu W, Lee Y, Lee Y, Chen C. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma. Int J Clin Exp Pathol. 2015;8:5642-9 pubmed
  89. Mohammed H, Russell I, Stark R, Rueda O, Hickey T, Tarulli G, et al. Progesterone receptor modulates ERα action in breast cancer. Nature. 2015;523:313-7 pubmed publisher
  90. Mundim F, Pasini F, Brentani M, Soares F, Nonogaki S, Waitzberg A. MYC is expressed in the stromal and epithelial cells of primary breast carcinoma and paired nodal metastases. Mol Clin Oncol. 2015;3:506-514 pubmed
  91. Cheung S, Boey Y, Koh V, Thike A, Lim J, Iqbal J, et al. Role of epithelial-mesenchymal transition markers in triple-negative breast cancer. Breast Cancer Res Treat. 2015;152:489-98 pubmed publisher
  92. Forse C, Agarwal S, Pinnaduwage D, Gertler F, Condeelis J, Lin J, et al. Menacalc, a quantitative method of metastasis assessment, as a prognostic marker for axillary node-negative breast cancer. BMC Cancer. 2015;15:483 pubmed publisher
  93. Gustbée E, Tryggvadottir H, Markkula A, Simonsson M, Nodin B, Jirström K, et al. Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients. BMC Clin Pathol. 2015;15:8 pubmed publisher
  94. Michaelidou K, Ardavanis A, Scorilas A. Clinical relevance of the deregulated kallikrein-related peptidase 8 mRNA expression in breast cancer: a novel independent indicator of disease-free survival. Breast Cancer Res Treat. 2015;152:323-36 pubmed publisher
  95. Goodman C, Sato T, Peck A, Girondo M, Yang N, Liu C, et al. Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism. Oncogene. 2016;35:1373-85 pubmed publisher
  96. Joshi P, Waterhouse P, Kannan N, Narala S, Fang H, Di Grappa M, et al. RANK Signaling Amplifies WNT-Responsive Mammary Progenitors through R-SPONDIN1. Stem Cell Reports. 2015;5:31-44 pubmed publisher
  97. Koh V, Lim J, Thike A, Cheok P, Thu M, Tan V, et al. Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients. Breast Cancer Res Treat. 2015;152:293-304 pubmed publisher
  98. Winczura P, Sosińska Mielcarek K, Duchnowska R, Badzio A, Lakomy J, Majewska H, et al. Immunohistochemical Predictors of Bone Metastases in Breast Cancer Patients. Pathol Oncol Res. 2015;21:1229-36 pubmed publisher
  99. de Deus Moura R, Carvalho F, Bacchi C. Breast cancer in very young women: Clinicopathological study of 149 patients ≤25 years old. Breast. 2015;24:461-7 pubmed publisher
  100. Nwafor C, Keshinro S. Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: Private practice experience. Niger J Clin Pract. 2015;18:553-8 pubmed publisher
  101. Mote P, Gompel A, Howe C, Hilton H, Sestak I, Cuzick J, et al. Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial. Breast Cancer Res Treat. 2015;151:309-18 pubmed publisher
  102. Miracco C, Toscano M, Butorano M, Baldino G, Tacchini D, Barone A, et al. Unusual clear cell, lymphoplasmacyte-rich, dural-based tumor with divergent differentiation: a tricky case mimicking a meningioma. Hum Pathol. 2015;46:1050-6 pubmed publisher
  103. Nakada S, Minato H, Takegami T, Kurose N, Ikeda H, Kobayashi M, et al. NAB2-STAT6 fusion gene analysis in two cases of meningeal solitary fibrous tumor/hemangiopericytoma with late distant metastases. Brain Tumor Pathol. 2015;32:268-74 pubmed publisher
  104. Falkenberg N, Anastasov N, Schaub A, Radulovic V, Schmitt M, Magdolen V, et al. Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221. Oncotarget. 2015;6:8103-14 pubmed
  105. Geels Y, van der Putten L, van Tilborg A, Lurkin I, Zwarthoff E, Pijnenborg J, et al. Immunohistochemical and genetic profiles of endometrioid endometrial carcinoma arising from atrophic endometrium. Gynecol Oncol. 2015;137:245-51 pubmed publisher
  106. Eom K, Jang M, Park S, Kang E, Kim S, Kim J, et al. The Expression of Carbonic Anhydrase (CA) IX/XII and Lymph Node Metastasis in Early Breast Cancer. Cancer Res Treat. 2016;48:125-32 pubmed publisher
  107. Quiroga Garza G, Lee J, El Naggar A, Black J, Amrikachi M, Zhai Q, et al. Sclerosing mucoepidermoid carcinoma with eosinophilia of the thyroid: more aggressive than previously reported. Hum Pathol. 2015;46:725-31 pubmed publisher
  108. Rusz O, Vörös A, Varga Z, Kelemen G, Uhercsák G, Nikolényi A, et al. One-Year Neoadjuvant Endocrine Therapy in Breast Cancer. Pathol Oncol Res. 2015;21:977-84 pubmed publisher
  109. Kim S, Lee Y, Koo J. Differential expression of lipid metabolism-related proteins in different breast cancer subtypes. PLoS ONE. 2015;10:e0119473 pubmed publisher
  110. Oon M, Thike A, Tan S, Tan P. Cancer stem cell and epithelial-mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast. Breast Cancer Res Treat. 2015;150:31-41 pubmed publisher
  111. Simons M, Nagtegaal I, Overbeek L, Flucke U, Massuger L, Bulten J. A patient with a noninvasive mucinous ovarian borderline tumor presenting with late pleural metastases. Int J Gynecol Pathol. 2015;34:143-50 pubmed publisher
  112. Muscatello L, Sarli G, Beha G, Asproni P, Millanta F, Poli A, et al. Validation of tissue microarray for molecular profiling of canine and feline mammary tumours. J Comp Pathol. 2015;152:153-60 pubmed publisher
  113. Argon A, Şener A, Zekioğlu O, Kapkaç M, Özdemir N. The effect of freezing on the immunoprofile of breast carcinoma cells. Balkan Med J. 2014;31:335-9 pubmed publisher
  114. Park S, Kim H, Koo J. Differential expression of cancer-associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer. Breast Cancer Res Treat. 2015;149:727-41 pubmed publisher
  115. Hole S, Pedersen A, Hansen S, Lundqvist J, Yde C, Lykkesfeldt A. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane. Int J Oncol. 2015;46:1481-90 pubmed publisher
  116. Rajaram R, Buric D, Caikovski M, Ayyanan A, Rougemont J, Shan J, et al. Progesterone and Wnt4 control mammary stem cells via myoepithelial crosstalk. EMBO J. 2015;34:641-52 pubmed publisher
  117. Tökés A, Szász A, Geszti F, Lukács L, Kenessey I, Turányi E, et al. Expression of proliferation markers Ki67, cyclin A, geminin and aurora-kinase A in primary breast carcinomas and corresponding distant metastases. J Clin Pathol. 2015;68:274-82 pubmed publisher
  118. Kim G, Lee J, Choi Y, Lee K, Lee J, Nam J, et al. Expression of matrix metalloproteinases and their inhibitors in different immunohistochemical-based molecular subtypes of breast cancer. BMC Cancer. 2014;14:959 pubmed publisher
  119. Liu J, Yu Y, Sun J, He S, Wang X, Yin J, et al. Clinicopathologic characteristics and prognosis of primary squamous cell carcinoma of the breast. Breast Cancer Res Treat. 2015;149:133-40 pubmed publisher
  120. Buell Gutbrod R, Cavallo A, Lee N, Montag A, Gwin K. Heart and Neural Crest Derivatives Expressed Transcript 2 (HAND2): a novel biomarker for the identification of atypical hyperplasia and Type I endometrial carcinoma. Int J Gynecol Pathol. 2015;34:65-73 pubmed publisher
  121. Tamega A, Miot H, Moço N, Silva M, Marques M, Miot L. Gene and protein expression of oestrogen-β and progesterone receptors in facial melasma and adjacent healthy skin in women. Int J Cosmet Sci. 2015;37:222-8 pubmed publisher
  122. Panis C, Pizzatti L, Corrêa S, Binato R, Lemos G, Herrera A, et al. The positive is inside the negative: HER2-negative tumors can express the HER2 intracellular domain and present a HER2-positive phenotype. Cancer Lett. 2015;357:186-95 pubmed publisher
  123. Kunasegaran K, Ho V, Chang T, De Silva D, Bakker M, Christoffels V, et al. Transcriptional repressor Tbx3 is required for the hormone-sensing cell lineage in mammary epithelium. PLoS ONE. 2014;9:e110191 pubmed publisher
  124. Nguyen D, Ouyang H, Mao J, Hlatky L, Barcellos Hoff M. Distinct luminal-type mammary carcinomas arise from orthotopic Trp53-null mammary transplantation of juvenile versus adult mice. Cancer Res. 2014;74:7149-58 pubmed publisher
  125. Baccelli I, Stenzinger A, Vogel V, Pfitzner B, Klein C, Wallwiener M, et al. Co-expression of MET and CD47 is a novel prognosticator for survival of luminal breast cancer patients. Oncotarget. 2014;5:8147-60 pubmed
  126. Megas G, Chrisofos M, Anastasiou I, Tsitlidou A, Choreftaki T, Deliveliotis C. Estrogen receptor (α and β) but not androgen receptor expression is correlated with recurrence, progression and survival in post prostatectomy T3N0M0 locally advanced prostate cancer in an urban Greek population. Asian J Androl. 2015;17:98-105 pubmed publisher
  127. Kuroda N, Fujishima N, Hayes M, Moritani S, Ichihara S. Encapsulated papillary carcinoma, apocrine type, of the breast. Malays J Pathol. 2014;36:139-43 pubmed
  128. Carvalho F, Bacchi L, Pincerato K, van de Rijn M, Bacchi C. Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil. BMC Womens Health. 2014;14:102 pubmed publisher
  129. Cha Y, Han S, Seol H, Oh D, Im S, Bang Y, et al. Immunohistochemical features associated with sensitivity to lapatinib-plus-capecitabine and resistance to trastuzumab in HER2-positive breast cancer. Anticancer Res. 2014;34:4275-80 pubmed
  130. Mingels M, Masadah R, Geels Y, Otte Holler I, de Kievit I, van der Laak J, et al. High prevalence of atypical hyperplasia in the endometrium of patients with epithelial ovarian cancer. Am J Clin Pathol. 2014;142:213-21 pubmed publisher
  131. Fujiwara S, Hung M, Yamamoto Ibusuk C, Yamamoto Y, Yamamoto S, Tomiguchi M, et al. The localization of HER4 intracellular domain and expression of its alternately-spliced isoforms have prognostic significance in ER+ HER2- breast cancer. Oncotarget. 2014;5:3919-30 pubmed
  132. Syed B, Green A, Nolan C, Morgan D, Ellis I, Cheung K. Biological characteristics and clinical outcome of triple negative primary breast cancer in older women - comparison with their younger counterparts. PLoS ONE. 2014;9:e100573 pubmed publisher
  133. Ulrich D, Tan K, Deane J, Schwab K, Cheong A, Rosamilia A, et al. Mesenchymal stem/stromal cells in post-menopausal endometrium. Hum Reprod. 2014;29:1895-905 pubmed publisher
  134. Chen F, Li A, Gao S, Hollern D, Williams M, Liu F, et al. Tip30 controls differentiation of murine mammary luminal progenitor to estrogen receptor-positive luminal cell through regulating FoxA1 expression. Cell Death Dis. 2014;5:e1242 pubmed publisher
  135. van der Post R, Bult P, Vogelaar I, Ligtenberg M, Hoogerbrugge N, van Krieken J. HNF4A immunohistochemistry facilitates distinction between primary and metastatic breast and gastric carcinoma. Virchows Arch. 2014;464:673-9 pubmed publisher
  136. Balk Møller E, Kim J, Hopkinson B, Timmermans Wielenga V, Petersen O, Villadsen R. A marker of endocrine receptor-positive cells, CEACAM6, is shared by two major classes of breast cancer: luminal and HER2-enriched. Am J Pathol. 2014;184:1198-208 pubmed publisher
  137. Mountzios G, Aivazi D, Kostopoulos I, Kourea H, Kouvatseas G, Timotheadou E, et al. Differential expression of the insulin-like growth factor receptor among early breast cancer subtypes. PLoS ONE. 2014;9:e91407 pubmed publisher
  138. Melchor L, Molyneux G, Mackay A, Magnay F, Atienza M, Kendrick H, et al. Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models. J Pathol. 2014;233:124-37 pubmed publisher
  139. Liu Y, Nenutil R, Appleyard M, Murray K, Boylan M, Thompson A, et al. Lack of correlation of stem cell markers in breast cancer stem cells. Br J Cancer. 2014;110:2063-71 pubmed publisher
  140. Park H, Jang M, Kim E, Kim H, Lee H, Kim Y, et al. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Mod Pathol. 2014;27:1212-22 pubmed publisher
  141. Chang T, Kunasegaran K, Tarulli G, De Silva D, Voorhoeve P, Pietersen A. New insights into lineage restriction of mammary gland epithelium using parity-identified mammary epithelial cells. Breast Cancer Res. 2014;16:R1 pubmed publisher
  142. Balko J, Giltnane J, Wang K, Schwarz L, Young C, Cook R, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014;4:232-45 pubmed publisher
  143. Faupel Badger J, Duggan M, Sherman M, Garcia Closas M, Yang X, Lissowska J, et al. Prolactin receptor expression and breast cancer: relationships with tumor characteristics among pre- and post-menopausal women in a population-based case-control study from Poland. Horm Cancer. 2014;5:42-50 pubmed publisher
  144. Dong P, Kaneuchi M, Xiong Y, Cao L, Cai M, Liu X, et al. Identification of KLF17 as a novel epithelial to mesenchymal transition inducer via direct activation of TWIST1 in endometrioid endometrial cancer. Carcinogenesis. 2014;35:760-8 pubmed publisher
  145. Li Q, Coulson H, Klaassen Z, Sharma S, Ramalingam P, Moses K, et al. Emerging association between androgen deprivation therapy and male meningioma: significant expression of luteinizing hormone-releasing hormone receptor in male meningioma. Prostate Cancer Prostatic Dis. 2013;16:387-90 pubmed publisher
  146. Kusafuka K, Onitsuka T, Muramatsu K, Miki T, Murai C, Suda T, et al. Salivary duct carcinoma with rhabdoid features: report of 2 cases with immunohistochemical and ultrastructural analyses. Head Neck. 2014;36:E28-35 pubmed publisher
  147. Kuhn E, Ayhan A, Shih I, Seidman J, Kurman R. Ovarian Brenner tumour: a morphologic and immunohistochemical analysis suggesting an origin from fallopian tube epithelium. Eur J Cancer. 2013;49:3839-49 pubmed publisher
  148. Dewaele B, Przybyl J, Quattrone A, Finalet Ferreiro J, Vanspauwen V, Geerdens E, et al. Identification of a novel, recurrent MBTD1-CXorf67 fusion in low-grade endometrial stromal sarcoma. Int J Cancer. 2014;134:1112-22 pubmed publisher
  149. Hagan C, Knutson T, Lange C. A Common Docking Domain in Progesterone Receptor-B links DUSP6 and CK2 signaling to proliferative transcriptional programs in breast cancer cells. Nucleic Acids Res. 2013;41:8926-42 pubmed publisher
  150. Zhang J, Wang Y, Yin Q, Zhang W, Zhang T, Niu Y. An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy. Int J Clin Exp Pathol. 2013;6:1380-91 pubmed
  151. Hao J, Yang C, Liu F, Yang Y, Li S, Li W, et al. Accessory breast cancer occurring concurrently with bilateral primary invasive breast carcinomas: a report of two cases and literature review. Cancer Biol Med. 2012;9:197-201 pubmed publisher
  152. Joensuu K, Leidenius M, Kero M, Andersson L, Horwitz K, Heikkila P. ER, PR, HER2, Ki-67 and CK5 in Early and Late Relapsing Breast Cancer-Reduced CK5 Expression in Metastases. Breast Cancer (Auckl). 2013;7:23-34 pubmed publisher
  153. Zhao Y, Park S, Bagchi M, Taylor R, Katzenellenbogen B. The coregulator, repressor of estrogen receptor activity (REA), is a crucial regulator of the timing and magnitude of uterine decidualization. Endocrinology. 2013;154:1349-60 pubmed publisher
  154. Escobar J, Klimowicz A, Dean M, Chu P, Nation J, Nelson G, et al. Quantification of ER/PR expression in ovarian low-grade serous carcinoma. Gynecol Oncol. 2013;128:371-6 pubmed publisher
  155. Gallardo A, Lerma E, Escuin D, Tibau A, Munoz J, Ojeda B, et al. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer. 2012;106:1367-73 pubmed publisher
  156. Wang N, Geng L, Zhang S, He B, Wang J. Expression of PRB, FKBP52 and HB-EGF relating with ultrasonic evaluation of endometrial receptivity. PLoS ONE. 2012;7:e34010 pubmed publisher
  157. Yamada Y, Yamamoto H, Ohishi Y, Nishiyama K, Fukuhara M, Saitou T, et al. Sclerosing variant of perivascular epithelioid cell tumor in the female genital organs. Pathol Int. 2011;61:768-72 pubmed publisher
  158. Chu P, Hsu N, Liao A, Shih N, Hou M, Liu C. Overexpression of ?-enolase correlates with poor survival in canine mammary carcinoma. BMC Vet Res. 2011;7:62 pubmed publisher
  159. Tieszen C, Goyeneche A, Brandhagen B, Ortbahn C, Telleria C. Antiprogestin mifepristone inhibits the growth of cancer cells of reproductive and non-reproductive origin regardless of progesterone receptor expression. BMC Cancer. 2011;11:207 pubmed publisher
  160. Meyer D, Brinkhaus H, Müller U, Muller M, Cardiff R, Bentires Alj M. Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors. Cancer Res. 2011;71:4344-51 pubmed publisher
  161. Teng Y, Tan W, Thike A, Cheok P, Tse G, Wong N, et al. Mutations in the epidermal growth factor receptor (EGFR) gene in triple negative breast cancer: possible implications for targeted therapy. Breast Cancer Res. 2011;13:R35 pubmed publisher
  162. Baydar D, Kulac I, Gurel B, De Marzo A. A case of prostatic adenocarcinoma with aberrant p63 expression: presentation with detailed immunohistochemical study and FISH analysis. Int J Surg Pathol. 2011;19:131-6 pubmed publisher